Vaccinal Prevention of Lower Respiratory Tract Pneumococcal Disease in Adults Without Immunosuppression

Vaccinal Prevention of Lower Respiratory Tract Pneumococcal Disease in Adults Without Immunosuppression

Community-acquired pneumonia (CAP) remains one of the major healthcare problems globally. Pneumococcal disease is the leading cause of deaths among vaccine preventable diseases in children and adults. Plain polysaccharide vaccine PPSV-23 and conjugated pneumococcal polysaccharide vaccine PCV-13 are...

Full description

Saved in:

Bibliographic Details
Main Author:	I. A. Guchev
Format:	Article
Language:	Russian
Published:	LLC "Publishing House OKI" 2020-05-01
Series:	Антибиотики и Химиотерапия
Subjects:	community-acquired pneumonia pneumococcal disease vaccination pneumococcal conjugate vaccine pneumococcal polysaccharide vaccine
Online Access:	https://www.antibiotics-chemotherapy.ru/jour/article/view/678
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Global distribution and characteristics of pneumococcal serotypes in adults
by: Haruka Maeda, et al.
Published: (2025-12-01)

Strategies for pneumococcal vaccination in older adults in the coming era
by: Kei Nakashima, et al.
Published: (2024-12-01)

Vaccine Prevention of Pneumococcal Infection in Children
by: Alexander A. Baranov, et al.
Published: (2018-07-01)

Vaccinal Prevention of Pneumococcal Infection in Children
by: A. A. Baranov, et al.
Published: (2015-12-01)

Efficacy of conjugate vaccines in pneumococcal infection prevention
by: A. L. Perova, et al.
Published: (2014-09-01)

The New Era of Pneumococcal Vaccination in Adults: What Is Next?
by: Lale Ozisik
Published: (2025-05-01)

The Analysis of Scientific Data on the Efficacy of Pneumococcal Conjugated Vaccine in the Cohort of Children with Bronchial Asthma
by: Tatiana A. Kaliuzhnaia, et al.
Published: (2020-11-01)

An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population
by: Ann-Charlotte Fridh, et al.
Published: (2024-12-01)

Pneumococcal vaccination in older adults: A useful, but underused weapon
by: Filipić Brankica
Published: (2025-01-01)

NEXT GENERATION PNEUMOCOCCAL CONJUGATE VACCINES EFFICACY AND EFFECTIVENESS IN DIFFERENT REGIONS OF THE WORLD
by: O. P. Kovtun, et al.
Published: (2014-01-01)

EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE: EMERGING DATA FROM INVASIVE PNEUMOCOCCAL DISEASE, PNEUMONIA, ACUTE OTITIS MEDIA AND NASOPHARYNGEAL CARRIAGE
by: Ralf Rene Reinert, et al.
Published: (2012-06-01)

Review of global use of licensed vaccines and development of new vaccines for the prevention of pneumococcal infection
by: M. V. Savkina, et al.
Published: (2021-12-01)

What do Patients Know About Pneumococcal Vaccine?
by: Fatma Çiftci, et al.
Published: (2017-08-01)

Effectiveness of pneumococcal conjugate 13-valent vaccine against severe pneumonia in Panama: a matched case-control study
by: Jacqueline Levy, et al.
Published: (2025-07-01)

Epidemiological and etiological characteristics of community-acquired pneumonia in conscripts in the modern period. Comparative evaluation of the effectiveness of pneumococcal vaccines
by: P. V. Kulikov, et al.
Published: (2019-05-01)

Epidemiology of Streptococcus pneumoniae serotypes in children before and after pneumococcal vaccination
by: I. N. Protasova, et al.
Published: (2021-12-01)

Pneumococcal vaccine hyporesponsiveness in people living with HIV: A narrative review of immunological mechanisms and insights from minimally invasive lymph node sampling
by: Giovanni E. Loe-Sack-Sioe, et al.
Published: (2025-12-01)

The effectiveness of immunization of children against Pneumococcal infection in Penza, Russia
by: O. N. Lesina, et al.
Published: (2019-04-01)

Bronchopulmonary Pathology Prevalence Among Premature infants and Estimation of Prophylactic Efficacy and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Premature infants with Bronchopulmonary Dysplasia
by: Vladislav V. Semerikov, et al.
Published: (2020-02-01)

Serotype distribution of invasive and non-invasive pneumococcal disease in children ≤5 years of age following the introduction of 10- and 13-valent pneumococcal conjugate vaccines in infant national immunization programs: a systematic literature review
by: Patricia Izurieta, et al.
Published: (2025-05-01)

Pneumococcal Vaccine Uptake in Adults Before and After Hospitalization for Pneumococcal Infections in Hong Kong, 2015 to 2024
by: King-Pui Florence Chan, et al.
Published: (2025-05-01)

A population-based study on the burden of hospitalized pediatric pneumococcal disease in Taiwan before and after the introduction of 13-valent pneumococcal conjugate vaccine into the childhood immunization program in 2015
by: Ting-An Yen, et al.
Published: (2025-02-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012-02-01)

The Results of a Three-Year Pneumococcal Vaccination of Children in Russia
by: Nikolay I. Briko, et al.
Published: (2018-10-01)

Clinical burden of pneumococcal disease among adults in France: A retrospective cohort study
by: M. Doyinsola Bailey, et al.
Published: (2025-12-01)

Serotype distribution of invasive and non-invasive pneumococcal disease in adults ≥65 years of age following the introduction of 10- and 13-valent pneumococcal conjugate vaccines in infant national immunization programs: a systematic literature review
by: Patricia Izurieta, et al.
Published: (2025-05-01)

A decade of 10-valent pneumococcal conjugate vaccine use in Lithuania: trends in invasive pneumococcal serotype dynamics
by: Aurelija Petrutienė, et al.
Published: (2025-08-01)

Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children
by: Edward Mezones-Holguín, et al.
Published: (2014-12-01)

Real-World Impact of Pneumococcal Conjugate Vaccines on Vaccine Serotypes and Potential Cross-Reacting Non-Vaccine Serotypes
by: Kevin Apodaca, et al.
Published: (2025-06-01)

EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
by: M. V. Fedoseenko, et al.
Published: (2014-09-01)

Modern Approaches to Vaccinal Prevention of a Pneumococcal Infection in Adults Patients with Diabetes Mellitus (Literature Review)
by: J. A. Paramonova, et al.
Published: (2018-04-01)

Prophylaxis of Community-Acquired Pneumonia Outbreaks with Pneumococcal Polysaccharide Vaccine. Prospects Analysis for Russian Military Community
by: I. A. Guchev, et al.
Published: (2020-05-01)

Cost-effectiveness of vaccination against pneumococcal infection of adults at risk within the federal and regional programs
by: A. V. Rudakova, et al.
Published: (2019-12-01)

Preventive effects of 23-valent pneumococcal polysaccharide vaccine on community-acquired pneumonia hospitalization in older individuals in China: A case-control study
by: Na Liu, et al.
Published: (2024-12-01)

Invasive Pneumococcal Disease burden and PCV coverage in children under five in Southeast Asia: implications for India
by: Shafi Kolhapure, et al.
Published: (2021-06-01)

Pneumococcal Infection and Vaccination-Related Knowledge, Attitudes and Practices Among Saudi Residents
by: Wed S. Althobaiti, et al.
Published: (2025-07-01)

Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up
by: Lili Huang, et al.
Published: (2025-12-01)

Serotype distribution among adults with community-acquired pneumococcal pneumonia in Japan between 2019 and 2022: A multicenter observational study
by: Haruka Maeda, et al.
Published: (2025-12-01)

Pneumococcal serotype prevalence and antibiotic resistance in children in South and Southeast Asia, 2012–2024
by: Tzou-Yien Lin, et al.
Published: (2024-12-01)

THE EXPERIENCE OF PNEUMOCOCCAL CONJUGATE VACCINE USAGE IN ORPHANAGE INSTITUTION OF THE REPUBLIC OF MORDOVIA
by: A. A. Brovkina, et al.
Published: (2012-11-01)